Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Tiziana Life SciencesExicureSol-Gel TechnologiesHeat BiologicsMilestone Pharmaceuticals
SymbolNASDAQ:TLSANASDAQ:XCURNASDAQ:SLGLNASDAQ:HTBXNASDAQ:MIST
Price Information
Current Price$3.12$1.94$13.02$6.90$5.33
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.21.51.21.61.4
Analysis Score3.53.53.53.53.4
Community Score2.33.02.33.02.6
Dividend Score0.00.00.00.00.0
Ownership Score0.00.80.00.80.8
Earnings & Valuation Score0.00.00.00.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$9.50$9.60$21.00$20.00$14.60
% Upside from Price Target204.49% upside394.85% upside61.29% upside189.86% upside173.92% upside
Trade Information
Market Cap$171.47 million$178.56 million$258.95 million$188.54 million$168.03 million
Beta1.412.211.360.324.2
Average Volume976,659628,25151,8882,293,486105,851
Sales & Book Value
Annual RevenueN/A$1.30 million$22.90 million$3.05 millionN/A
Price / SalesN/A131.2611.5957.48N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value($0.09) per share$0.94 per share$2.57 per share$2.73 per share$4.69 per share
Price / BookN/A2.065.072.53N/A
Profitability
Net Income$-9,320,000.00$-26,300,000.00$-24,610,000.00$-20,020,000.00$-55,230,000.00
EPS($0.03)($0.46)($1.26)N/A($3.50)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-127.52%-273.92%-527.90%N/A
Return on Equity (ROE)N/A-24.26%-48.54%-44.07%-58.89%
Return on Assets (ROA)N/A-19.41%-42.14%-36.38%-55.37%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio1.86%6.22%8.55%31.34%18.26%
Quick RatioN/A6.22%8.55%31.34%18.27%
Ownership Information
Institutional Ownership PercentageN/A44.15%30.88%49.84%51.88%
Insider Ownership PercentageN/A26.70%N/A5.50%4.16%
Miscellaneous
Employees857653628
Shares Outstanding64.22 million87.96 million20.39 million25.41 million29.85 million
Next Earnings Date6/16/2021 (Estimated)5/13/2021 (Estimated)5/13/2021 (Estimated)5/21/2021 (Estimated)5/13/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Milestone Pharmaceuticals Stock Is a Bet On EtripamilMilestone Pharmaceuticals Stock Is a Bet On Etripamil
feedproxy.google.com - April 2 at 12:21 PM
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) to Post FY2021 Earnings of ($1.92) Per Share, Jefferies Financial Group ForecastsMilestone Pharmaceuticals Inc. (NASDAQ:MIST) to Post FY2021 Earnings of ($1.92) Per Share, Jefferies Financial Group Forecasts
americanbankingnews.com - April 2 at 8:36 AM
Q1 2021 EPS Estimates for Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Boosted by OppenheimerQ1 2021 EPS Estimates for Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Boosted by Oppenheimer
americanbankingnews.com - April 2 at 7:48 AM
Research Analysts Issue Forecasts for Milestone Pharmaceuticals Inc.s Q1 2021 Earnings (NASDAQ:MIST)Research Analysts Issue Forecasts for Milestone Pharmaceuticals Inc.'s Q1 2021 Earnings (NASDAQ:MIST)
americanbankingnews.com - April 1 at 7:16 AM
Milestone Pharmaceuticals (NASDAQ:MIST) Issues Earnings ResultsMilestone Pharmaceuticals (NASDAQ:MIST) Issues Earnings Results
americanbankingnews.com - March 30 at 7:46 AM
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Average Recommendation of "Buy" by AnalystsMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Average Recommendation of "Buy" by Analysts
americanbankingnews.com - March 30 at 6:38 AM
Milestone Pharmaceuticals: Q4 Earnings SnapshotMilestone Pharmaceuticals: Q4 Earnings Snapshot
theintelligencer.com - March 29 at 7:01 PM
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical and Corporate UpdateMilestone Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical and Corporate Update
prnewswire.com - March 29 at 5:50 PM
Should Investors Consider Buying These Top Health In March? 4 To WatchShould Investors Consider Buying These Top Health In March? 4 To Watch
nasdaq.com - March 5 at 5:35 PM
PLx Pharma Receives FDA Approval of SNDAs for Both VAZALORE 325 mg and 81 mg Nasdaq:PLXPPLx Pharma Receives FDA Approval of SNDAs for Both VAZALORE 325 mg and 81 mg Nasdaq:PLXP
compsmag.com - March 1 at 3:08 PM
How Much Of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Do Institutions Own?How Much Of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Do Institutions Own?
finance.yahoo.com - February 1 at 3:11 PM
Amphastar Announces Approval for Glucagon for Injection Kit, 1mgAmphastar Announces Approval for Glucagon for Injection Kit, 1mg
wallstreet-online.de - December 29 at 9:32 AM
MIST Jan 2021 7.500 callMIST Jan 2021 7.500 call
uk.finance.yahoo.com - December 28 at 10:48 PM
MIST Jan 2021 7.500 putMIST Jan 2021 7.500 put
uk.finance.yahoo.com - December 28 at 10:48 PM
MIST Jan 2021 10.000 callMIST Jan 2021 10.000 call
uk.finance.yahoo.com - December 24 at 1:18 AM
Lobe Sciences Ltd.: Lobe Sciences Commences Engineering of Nasal Mist DeviceLobe Sciences Ltd.: Lobe Sciences Commences Engineering of Nasal Mist Device
finanznachrichten.de - December 3 at 8:25 AM
Is Milestone Pharmaceuticals (MIST) A Good Stock To Buy Now?Is Milestone Pharmaceuticals (MIST) A Good Stock To Buy Now?
finance.yahoo.com - December 2 at 10:24 PM
TAICCA and Golden Horse FPP Series Introduce Promising Proposals to International InvestorsTAICCA and Golden Horse FPP Series Introduce Promising Proposals to International Investors
finance.yahoo.com - December 2 at 7:46 AM
Government of Canada Creates Task Force on Flood Insurance and RelocationGovernment of Canada Creates Task Force on Flood Insurance and Relocation
finance.yahoo.com - November 23 at 10:04 PM
First patient enrolled in Milestone Pharmaceuticals late-stage study of etripamil in PSVTFirst patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT
seekingalpha.com - November 18 at 8:38 AM
Milestone Pharmaceuticals Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVTMilestone Pharmaceuticals Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT
finance.yahoo.com - November 18 at 8:38 AM
Milestone Pharmaceuticals EPS beats by $0.09Milestone Pharmaceuticals EPS beats by $0.09
seekingalpha.com - November 13 at 12:35 PM
Milestone Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Corporate UpdateMilestone Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Corporate Update
finance.yahoo.com - November 13 at 7:24 AM
Milestone Pharmaceuticals to Present at the Jefferies Virtual London Healthcare ConferenceMilestone Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
finance.yahoo.com - November 11 at 8:38 AM
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q3 2020 Results - Earnings Call TranscriptEyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 11 at 3:37 AM
DateCompanyBrokerageAction
12/22/2020Tiziana Life SciencesB. RileyInitiated Coverage
9/21/2020Tiziana Life SciencesHC WainwrightReiterated Rating
9/10/2019Tiziana Life SciencesLaidlawSet Price Target
12/18/2020ExicureBMO Capital MarketsInitiated Coverage
9/17/2020ExicureChardan CapitalBoost Price Target
6/4/2020ExicureGuggenheimReiterated Rating
6/4/2020ExicureLADENBURG THALM/SH SHReiterated Rating
9/1/2020Sol-Gel TechnologiesRaymond JamesReiterated Rating
12/31/2019Sol-Gel TechnologiesJefferies Financial GroupBoost Price Target
12/31/2019Sol-Gel TechnologiesJMP SecuritiesBoost Price Target
3/2/2021Heat BiologicsCantor FitzgeraldInitiated Coverage
2/9/2021Heat BiologicsAlliance Global PartnersBoost Price Target
2/9/2021Heat BiologicsMaxim GroupReiterated Rating
7/29/2019Heat BiologicsBrookline Capital ManagementInitiated Coverage
7/9/2018Heat BiologicsEurobank EFGInitiated Coverage
7/29/2020Milestone PharmaceuticalsOppenheimerUpgrade
7/23/2020Milestone PharmaceuticalsCowenBoost Price Target
7/23/2020Milestone PharmaceuticalsPiper SandlerBoost Price Target
6/4/2019Milestone PharmaceuticalsCIBCInitiated Coverage
6/3/2019Milestone PharmaceuticalsPiper Jaffray CompaniesInitiated Coverage
(Data available from 4/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.